Jump to content

Bismacine

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Bismacine, also known as Chromacine, is a substance manufactured by American Biologics Corporation and marketed as a purported alternative treatment for Lyme disease. Bismacine contains high levels of bismuth, and two deaths are recorded following the use of intravenous bismacine to treat Lyme disease.[1] In 2006, the U.S. Food and Drug Administration warned consumers not to use bismacine, noting that it is ineffective and dangerous.[2]

References

  1. ^ Quirk M. (2006). "Alternative health therapy for Lyme disease results in death". Lancet Infect Dis. 6 (8): 546. doi:10.1016/S1473-3099(06)70563-1.
  2. ^ "FDA Warns Consumers and Health Care Providers Not to Use Bismacine, also known as Chromacine". U.S. Food and Drug Administration. 2006-06-21. Retrieved 2008-10-16.